Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer, and as one of our directors since our inception in 2007. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, a global pharmaceutical company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division; the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly; the Internal Medicine Division; the Lilly Clinic, Lilly’s dedicated Phase 1 unit; and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. He earned a BA, cum laude, from Yale University and an MD from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.
Dr. Bodick is a co-founder and has served as our Chief Medical Officer since our inception in 2007. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for early-phase clinical investigation at Lilly Research Laboratories. Dr. Bodick also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computer-based systems to support image-intensive diagnosis. Dr. Bodick holds 14 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health. Dr. Bodick earned an AB from Cornell University, a PhD in neuroscience from Columbia University, an MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.
Mr. Driscoll has served as our Chief Financial Officer since May 2013. Prior to joining us, Mr. Driscoll was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company since 2009. Previously, Mr. Driscoll also served as Chief Financial Officer from 2007 to 2008, and subsequently Chief Executive Officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company; Chief Financial Officer at Astraris, Inc., a private biotechnology company, from 2006 to 2007; and Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company, from 2002 to 2006. Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University.
Dr. Ballal brings more than 10 years of business and transactional experience to Flexion Therapeutics. Most recently, he was running business development at the Broad Institute where he completed the cancer stem cell transaction that founded Verastem Inc. (VSTM). Prior to the Broad, he worked as an associate at ASM Ventures and participated in their investments that included: A&G Pharmaceuticals, Marligen (sold to Origene), and Quosa (sold to Elsevier). Rahul started his career in Silicon Valley as the founder/CEO of Redmind, a venture backed data analytics startup that he sold to Ikimbo Inc., in 2002. Rahul has a PhD in cancer biology from Georgetown School of Medicine, an MS in bioinformatics from Johns Hopkins, and a BA from Brown University. He also completed his Kauffman Fellowship at Novartis Venture Funds.
Dr. Boen has extensive experience in the clinical development, medical affairs and risk management of pharmaceuticals. As a trained physician, he started his career in the industry more than 20 years ago at the global headquarters of Organon in the Netherlands where he was responsible for several global projects ranging from Phase 1 to Phase 3 in the area of female health. Subsequently he was assigned to setup and lead the global clinical development department at sister company Organon Teknika, where he carried responsibility for global clinical development, medical affairs, drug safety and risk management activities for the company’s full pharmaceutical portfolio, which included products in the area of anesthesia, pain management and bladder cancer. After Organon moved its headquarters to New Jersey, Dr. Boen headed global medical affairs for the company’s anesthesia products and became the medical lead for the development of new products in this area for Organon, Schering-Plough and Merck, respectively. Most recently, at Forest Research Institute, Dr. Boen headed the neurology clinical development group with clinical research projects in the area of pain management, neurodegenerative and neurodevelopmental disorders. He holds a medical degree from Utrecht University in the Netherlands.
Dr. Carmody brings over 20 years experience in the biopharmaceutical/pharmaceutical industry as a recognized leader with expertise driving vision in quality systems, control, assurance, validation and analytical development. Prior to joining Flexion Therapeutics, Dr. Carmody held various leadership positions in Quality Assurance, Quality Control, Validation and Analytical Development including founder and President of Avatar Pharmaceutical Services a FDA registered GMP contract research organization with a specialty in oligonucleotide analysis and characterization. In addition to this solid grounding in pharmaceuticals, she worked at Waters Corporation’s Applied Technology and Marketing groups where she developed novel separation methods with colleagues and customers. Dr. Carmody holds a Ph.D. in Analytical Chemistry from Clark University in Worcester, Massachusetts.
Ms. Davidson has more than 20 years of broad corporate finance experience encompassing treasury management, strategic planning, operations finance, and controllership. Most recently, she served as Director of Finance at OmniSonics Medical Technologies, Inc. Prior to that, she served in various finance, strategy and administration positions at Fisher Scientific International, Inc., Pepsi Bottling Group, and PerkinElmer Inc. Ms. Davidson has been involved in a number of M&A transactions, venture debt and equity financing totaling $90 million, and numerous product launches. She holds a BA and an MBA, both from the University of New Hampshire.
Mr. Deardorf has more than 18 years of commercial biopharmaceutical experience encompassing marketing, business development, market development, program management and sales. Most recently, he provided strategic commercial guidance to biopharmaceutical start-up companies as an independent consultant. Prior to that, he spent 14 years at Genzyme Corp. working on a variety of biomaterial, cell-based, and small molecule products in the orthopaedic market. Most notably, Mr. Deardorf was Vice President of Marketing for the Synvisc® franchise and led the extremely successful launch of Synvisc-One, an injectable product for osteoarthritis of the knee. He holds a BS in Biochemistry from California Polytechnic State University and an MBA from the Wharton School at the University of Pennsylvania.
Dr. Kumar joined Flexion Therapeutics with nearly 15 years of experience in drug discovery, pharmacology and preclinical development gained in large pharmaceutical companies, small biotech and a consulting company environment. She has experience advancing several small molecules and proteins into initial clinical development and continuing to support them through later stages of development and eventual regulatory approval. Dr. Kumar has worked in the area of inflammation in musculoskeletal, respiratory and cardiovascular diseases. She was previously Vice President of R&D at Clinquest, Inc. where she led the strategic drug development consulting team that worked on multiple programs in both the US and in Europe. Prior to that, she was Senior Director, Pharmacology at Critical Therapeutics, Inc. and Principal Scientist and Project Leader at Wyeth Research/Genetics Institute. She received her postdoctoral training at Pharmacia and Upjohn and holds a PhD in Bioengineering from Georgia Institute of Technology and a Bachelor’s in Chemical Engineering from the Indian Institute of Technology.
Ms. Willwerth has more than 20 years of experience in pharmaceutical development. She joined Flexion Therapeutics from Viacell, where she was a member of the company’s Executive Management team and served as Vice President, Product Development, with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs. Ms. Willwerth previously served as Senior Director, Product Development at The Medicines Company, where she focused on cardiovascular therapy clinical and product development. Prior to that, she held a number of ascendant clinical operations positions at Astra Pharmaceuticals and Biopure Corporation. Ms. Willwerth holds a BS in Biology, with high distinction, from Worcester Polytechnic Institute.